Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation

Abstract

Tissue factor activity (TFA) of 10(8) leukemia cells was measured in 82 patients with acute nonlymphoid leukemia by the clotting method. The TFA bore a significant correlation to the development of disseminated intravascular coagulation (DIC) in these cases. Mean TFA value with standard deviation (SD) was 8.3 +/- 6.3 U in 48 cases with DIC, which was significantly higher than 0.3 +/- 4.2 U in 34 cases without DIC. Whereas Mean TFA in non-M3 was 0.9 +/- 6.3 U which was significantly lower than 37.2 +/- 2.3 U in M3, some non-M3 showed TFA as high as M3 and were complicated by DIC. In heparin treatment, dosage of heparin could not be controlled by either APTT or AcCT but was controlled by the extent of TFA of leukemia cells. Retrospective analysis of clinical features revealed that 97000X + 9000 units/day (X = logarithm value of TFA) of heparin is an adequate dosage for the successful treatment of DIC when TFA of leukemia cells is 0.8 U or more.

Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy

“…As TF is expressed broadly in different types of tumors, including solid tumors (5,30,32,37,38) and leukemia (39), hlFVII-LDP-AE has a broad therapeutic potential for lung and other cancers (39)(40)(41). Figure 5.…”

Prediction of Disseminated Intravascular Coagulation in Patients with Leukemia.

“…Wehave previously shown that the severity of DIC in patients with acute myelogenous leukemia is significantly related to the TF activity of their leukemic cells, but not to the leukemic cell counts in peripheral blood and bone marrow (7,9). Amongthe three groups in the present study, no significant difference was observed in the leukemic cell counts at all.…”

“…1 mLof factor IX-deflcient plasma were incubated for 3 min at 37°C, after which 0.1 mL of 25 mmol/L CaCl2 solution was immediately blown into the mixture to determine the clotting time. The activity which gave 14 sec of clotting time was arbitrarily defined as 100 U/108 cells (8,9,20), and that which gave clotting time longer than 240 sec was defined as absent. The procoagulant activity of the same samples was also assayed using factor X-deficient plasma using the same procedure.…”

“…TF activity can be measured in virtually all leukemia patients by a simple clotting assay using bone marrow cells (2,8). Wehave reported previously that the severity of DIC in patients with acute leukemia is correlated to the TF activity of bone marrowcells on admission (9). Lyberg and associates (10) (1 1, 12).…”

The role of RAR and RXR activation in retinoid-induced tissue factor suppression

“…4 Acute promyelocytic leukaemia (APL) is the most common myeloid leukaemia associated with thrombotic complications, ultimately leading to DIC. 5 APL is a subtype of acute myelogenous leukaemia with the characteristic chromosome translocation that disrupts the retinoic acid receptor (RAR)-␣ gene on chromosome 17 and fuses it to the promyelocytic leukaemia (PML) gene at chromosome 15, thus resulting in the PML/RAR␣ fusion protein. Beyond pathological expression, TF is also expressed on the surface of bone marrow derived myeloid progenitor cells.…”